Patient-Oriented Evidence That Matters
Minimal Effect of ERT on Sexual Function in Menopausal Women
Am Fam Physician. 2018 Mar 15;97(6):408.
Does estrogen replacement therapy (ERT) affect sexual function in menopausal women?
Transdermal, but not oral, estrogen produced a small improvement in sexual function scores in menopausal women. The increases were very small and may not be noticeable by most women. Although the women in this study had low baseline sexual function scores, they were not necessarily distressed by the low scores, so this study did not evaluate women with sexual dysfunction. (Level of Evidence = 1b)
This study is part of a larger study investigating the role of estrogen replacement on atherosclerosis progression. Women less than three years from their last menstrual period (average age = 52.7 years) were recruited and randomized (using concealed allocation) to receive oral conjugated equine estrogens (0.45 mg per day), transdermal estradiol (50 mcg per day), or placebo for four years, with micronized progesterone for 12 days per month. The study used the Female Sexual Function Index (FSFI) to track sexual function, although the authors did not assess distress associated with low sexual function, which is needed for a diagnosis of sexual dysfunction. FSFI scores, on average, were low at the start of treatment (18.4 to 19.1 out of a possible 36), and 74% of women had a score that indicates low sexual function (less than 26.55). Over the course of the study, transdermal, but not oral, estrogen was associated with a small but statistically significant increase in FSFI scores (average efficacy = 2.6; 95% confidence interval, 1.11 to 4.10; P = .002), with significant improvements on the lubrication and pain subscales of the inventory. However, 67% of women treated with transdermal estrogen still had low sexual function.
Study design: Randomized controlled trial (double-blinded)
Funding source: Government
Setting: Outpatient (any)
Reference: Taylor HS, Tal A, Pal L, et al. Effects of oral vs transdermal estrogen therapy on sexual function in early postmenopause: ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS). JAMA Intern Med. 2017;177(10):1471–1479.
POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see http://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, Editor-in-Chief.
A collection of POEMs published in AFP is available at http://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
May 15, 2019
Access the latest issue of American Family Physician